Skip to main contentSkip to navigationSkip to search
Curasight

Press releases

2022

Interim Report January - March 2022

May 24, 2022
 | Regulatory
Curasight A/S (“Curasight” or “the Company” - TICKER: CURAS) hereby publishes the interim report for the period January 1 – March 31, 2022. The interim report is available as an attached file to this release and on the Company’s website. Below is a summary of the report.

Curasight to present at Kapital Partners Life Science seminar

May 16, 2022
 | Regulatory
Curasight A/S (TICKER: CURAS) announced today that Chief Executive Officer Ulrich Krasilnikoff and Chief Scientific Officer professor Andreas Kjær will give an update on company strategy and progress in developing new treatment options for cancer diseases, at Kapital Partners Life Science seminar, 18 May 2022.

Resolutions of the Annual General Meeting of Curasight A/S

April 27, 2022
 | Regulatory
Curasight A/S, CVR no. 35 24 93 89 (“Curasight” or the “Company”) held its Annual General Meeting on 27 April 2022 at 10:00 (CET) at the Company’s premises, Ole Maaløes Vej 3, room M7, DK-2200 Copenhagen N, Denmark.

Additional US patent application relating to uTRACE[®] is accepted for grant

April 22, 2022
 | Regulatory
The United States Patent and Trademark Office has announced that Curasight’s United States Patent Application no. 16/870,776 is ready for allowance and the patent will be issued with patent no. 1131137. The patent strengthens Curasights IP protection and supports the US commercial strategy. 

Notice of Annual General Meeting 2022

April 12, 2022
 | Regulatory
Copenhagen, Denmark, 12 April 2022 – Notice is hereby given of the annual general meeting of Curasight A/S (“Curasight” or the “Company”).

The Board of Directors is pleased to invite shareholders to the Annual General Meeting of Curasight A/S on

Wednesday 27 April 2022 at 10 am CET at COBIS, Ole Maaløes Vej 3, DK-2200 Copenhagen

Curasight announces new date of the Annual General Meeting and an updated financial calendar 2022

March 9, 2022
 | Regulatory
Copenhagen, Denmark, 9 March 2022 - Curasight A/S (“Curasight” or the “Company”) announces that the Company’s Annual General Meeting will be held on 27 April 2022 and an updated financial calendar for rest of 2022

Annual Report for the fiscal year 2021

February 24, 2022
 | Regulatory
Curasight A/S (“Curasight” or “the Company”) hereby publishes the Annual Report for the fiscal year of 2021. The Annual Report is available as an attached file to this release and on the Company’s website. Below is a summary of the report.

Year-end report October - December 2021

February 24, 2022
 | Regulatory
Curasight A/S (“Curasight” or “the Company”) hereby publishes the Year-end report for the period October 1 – December 31, 2021. The Year-end report is available as an attached file to this release and on the Company’s website. Below is a summary of the report.

Curasight expands its strategy and strengthen its position as a theranostic company

February 23, 2022
 | Regulatory
Copenhagen, Denmark, 23 February 2022 - Curasight A / S ("Curasight" or "The Company") announces today that it is expanding and accelerating its clinical programs with two additional cancer indications - Neuroendocrine tumors (NET) and head and neck cancer. Both indications will be pursued with regard to both diagnostics and therapy meaning that Curasight strengthens its position as a theranostic company.

Curasight strengthens its strategic position with the acquisition of TRT Innovations ApS

February 10, 2022
 | Regulatory
Copenhagen, Denmark, 10 February 2022 - Curasight A/S (“Curasight” or the “Company”) has today signed and completed an agreement to acquire the early-stage R&D company TRT Innovations ApS.  Curasight intends to expand and accelerate its clinical programs and is strengthening the therapeutic platform. 
Load more